Cannabis Sativa, Inc. (CBDS) announced today that the Company has granted an exclusive license to the Sowilde Management Group, Inc. (“Sowilde”) to allow Sowilde to produce products under the Company’s “hi” and “White Rabbit” brands.
White Rabbit offers fast acting low dose cannabis oral sprays and low dose cannabis mints. Both the spray and the mints are formulated as CBD, THC and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each.
hi Honey, is a rich, dark, Wild Raw Honey from African mountain bees that is infused with THC or CBD and sourced from a company that supports a native bee population as well as creates sustainable livelihoods for two indigenous groups.
“Sowilde Management Group understands the market uniqueness of these products for the rapidly growing industry. We believe Sowilde is a great fit to exploit our brands and intellectual property in the State of California,” said President David Tobias.
Sowilde Management Group (“Sowilde”) brands and distributes holistic cannabis supplements and infused products that empower patients to achieve a healthier lifestyle. Their proprietary formulations are based on a variety of the most effective medicinal compounds found within cannabis and provide a balanced, controlled experience. Rooted in science, conscientious living, and a passion for natural healthcare solutions, Sowilde is well-being made simple.
About Cannabis Sativa, Inc.:
Cannabis Sativa, Inc. (“CBDS”) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the “hi” and “White Rabbit” brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: Wild Earth Naturals, Inc., (wildearthnaturals.com), iBudtender (www.ibudtender.com) and PrestoDoctor (www.prestodoctor.com). In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company’s success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Mesquite, NV 89027